linjc16/ctgov huggingface dataset:
Single Embryo Transfer vs. Double Embryo Transfer in an Oocyte Donation Programme

Study Overview
=================
Brief Summary
-----------------
Experimental study to assess the efficacy of single embryo transfer (SET) with respect to double embryo transfer (DET) in an oocyte donation programme, 160 recipients will be randomized in two groups

Official Title
-----------------
A Prospective, Randomized, Controlled Trial Comparing SET vs DET in an Oocyte Donation Programme

Conditions
-----------------
Infertility, Oocyte Recipient, Single Embryo Transfer/Double Embryo Transfer, Cumulative Pregnancy Rate, Multiple Pregnancy

Intervention / Treatment
-----------------
* Other: Select the Number of embryos to transfer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients under their first or second cycle of a synchronous donation to have a minimum of 5 available embryos to transfer patients who accept transfers of frozen-thawed embryos Exclusion Criteria: medical indications to transfer only one embryo (Turner Syndrome, uterine surgical history, uterine myomas,…)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SET<br>Single embryo transfer | Other: Select the Number of embryos to transfer<br>* Select the Number of embryos to transfer<br>|
| Active Comparator: DET<br>Double embryo transfer | Other: Select the Number of embryos to transfer<br>* Select the Number of embryos to transfer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative pregnancy rate |  | at 12 months of fresh embryo transfer (time considered enough in order to do a minimum of one frozen-thawed cycle if pregnancy is not achieved with the fresh cycle | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative live birth rate |  |  | 
| Multiple pregnancy rate |  |  | 
| Time needed to achieve the pregnancy |  |  |
Comparison of Short- and Long-time Action Observation Training on Upper Limb Function in Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
To compared short- and long-time action observation training (AOT) in terms of grip strength, the Jebsen Taylor Hand Function Test (JTHF), the Quality of Upper Extremities Skills Test (QUEST), and the ABILHAND-Kids test.

Official Title
-----------------
Main Researcher for Action Observation Training (AOT)

Conditions
-----------------
Cerebral Palsy, Spastic

Intervention / Treatment
-----------------
* Other: Action observation training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages between 6 and 15 years confirmed diagnosis of spastic CP below grade 2 on the modified Ashworth scale between grade 4 and 8 on the house functional classification system ability to understand the assessor's instructions. Exclusion Criteria: severe spasticity in UL (MAS>2) orthopedic surgery in the UL within 6 months absence of sensory

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 30 min AOT<br> | Other: Action observation training<br>* Each child observed a task video and then performed a task<br>|
| Placebo Comparator: 60 min AOT<br> | Other: Action observation training<br>* Each child observed a task video and then performed a task<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of grip strength | Power of hand grip | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral palsy
CT Mar Technology and MR Mavric, Semac Sequence in Removing Artifacts of Orthopedic Metal Internal Fixation

Study Overview
=================
Brief Summary
-----------------
1. Objective to compare the effect of single energy imaging and mar technology in reducing artifacts of knee and hip replacement, and to explore the appropriate keV range of Mar technology in removing metal artifacts.,2. Objective to compare the effects of different MRI sequences (mavric / semac, stir, ideal, FSE) in removing artifacts of spinal internal fixation, knee and hip replacement.

Detailed Description
-----------------
Conventional spiral CT [4] examination will form black-and-white stripe artifacts around the metal implant, making the display of adjacent important structures unclear. In routine MRI examination [5], metal will interfere with the uniformity of local magnetic field, resulting in signal loss, and the artifacts will seriously affect the observation of bone and its surrounding structures. The purpose of this study was to comprehensively evaluate the effect of Mar technology on reducing metal artifacts after internal fixation and joint replacement, and then to explore the appropriate keV range of Mar technology to reduce metal artifacts. We also aim to compare the reduction effect of different sequences of MRI on internal fixation artifacts after internal fixation and joint replacement, and to explore the sequence suitable for clinical diagnosis and treatment.

Official Title
-----------------
Objective to Explore the Clinical Application Value of Spectral CT Mar Technology and Magnetic Resonance Mavric, Semac Sequence in Removing Artifacts of Orthopedic Metal Internal Fixation

Conditions
-----------------
Spinal Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Reduce metal artifacts examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients after spinal internal fixation or knee or hip replacement Exclusion Criteria: Patients with poor image quality caused by their own factors such as patients' movement can not meet the diagnostic requirements
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| conventional examination<br>patients undergo conventional examination | |
| Reduce metal artifacts examination<br>patients undergo reduce metal artifacts examination | Diagnostic Test: Reduce metal artifacts examination<br>* patients undergo reduce metal artifacts examination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Artifact index | AI in region of interest | 2020.10.15-2020.10.30 |
GW679769 In Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate safety, tolerability and efficacy of oral GW679769 up to 120 mg dose compared to placebo in patients with ACR(American College of Rheumatology)-defined fibromyalgia, co-morbid with depression.

Official Title
-----------------
An Outpatient, Randomised, Double-blind, Placebo Controlled, Parallel Group Exploratory Study to Evaluate Safety, Tolerability and Efficacy of GW679769 in Patients With Fibromyalgia Syndrome Comorbid With Depression.

Conditions
-----------------
Depression, Depressive Disorder, Fibromyalgia

Intervention / Treatment
-----------------
* Drug: GW679769


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Diagnosis of fibromyalgia (ACR criteria). Non-severe depression (HAM-D score >14 <24). Women must commit to consistent use of an acceptable method of birth control. Exclusion criteria: Severe depression (HAM-D score > 24). Unable to discontinue medications for pain or depression. Laboratory and ECG value at screening outside sponsor defined ranges. Positive to stool occult blood test.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GW679769|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Fibromyalgia Impact Questionnaire (FIQ) total score |  | throughout study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of GW679769 vs placebo in health-related quality of life outcomes |  | throughout study | 
| Relationship between PK of GW679769 and clinical outcome in patients |  | throughout study | 
| Safety and Tolerability |  | throughout study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Depression, NK1-antagonist, Fibromyalgia, GW679769, Outpatient
Acute Myocardial Infarction in Native Versus Non-native Young Population in Saudi Arabia

Study Overview
=================
Brief Summary
-----------------
A retrospective study collecting the data of young patients admitted with diagnosis of Acute Myocardial Infarction.

Detailed Description
-----------------
A retrospective study investigating young adults aged <45 years for males and <55 years for females admitted at Saud Al Babtain Cardiac Center with diagnosis of Acute Myocardial Infarction, determining its risk factors for Coronary Artery Disease (CAD) related to cultural characteristics and common positive consanguinity of parents as well as the prevalent diabetes and smoking.

Official Title
-----------------
Clinical Presentation and Outcome of Acute Myocardial Infarction in Native Versus Non-native Young Population in Saudi Arabia

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: <45 years old for male and <55 years old for female patients admitted with diagnosis of Acute Myocardial Infarction Exclusion Criteria: <17 and >55 years old male and female patients admitted with diagnosis other than Acute Myocardial Infarction.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 54 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of young adults hospitalized with primary diagnosis of Acute Myocadial Infarction. | Clinical Presentation and Outcome of Acute Myocardial Infarction in Native Versus Non-native Young Population in Saudi Arabia | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Young, Saudi
Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting

Study Overview
=================
Brief Summary
-----------------
The investigators prospectively studied the effect of aspirin on platelet function in 106 stable outpatients 6 months after successful percutaneous coronary angioplasty. Participants were randomized in a double-blind, double-crossover study (80 or 500 mg per day for 6 months).T

Detailed Description
-----------------
Background: Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery disease. There is controversy regarding the prevalence of aspirin resistance in patients with coronary artery disease and the effect of dose on resistance. Our primary aims were to determine the degree of platelet responsiveness to aspirin, and to study the influence of dose on platelet inhibition and clinical outcomes after coronary stenting.

Conditions
-----------------
Coronary Stenting

Intervention / Treatment
-----------------
* Drug: 80 mg ASA dosing
* Drug: 500 mg ASA dosing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 months post stent without complication Exclusion Criteria: subacute stent thrombosis unable to discontinue plavix dont accept to participate contraindication for ASA use

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 80 mg ASA dose<br>6 months post stent on 80 mg ASA | Drug: 80 mg ASA dosing<br> <br> |
| Active Comparator: 500 mg ASA dose<br>6 months posr stent on ASA alone | Drug: 500 mg ASA dosing<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| laboratory ASA resistance |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major adverse cardiac events and positive cardiac scan for ischemia |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ASA resistance, coronary stenting, platelet function, laboratory ASA resistance, MACE, Positive SPECT
New Techniques to Reduce Intra-operative Bleeding During Complex Liver Resection

Study Overview
=================
Brief Summary
-----------------
This observational study introduced an new advanced bleeding control strategy during complex liver resection.This newly described stepwise vascular control technique was efficacious and feasible to control intra-operative bleeding in complex hepatectomy involving second hepatic hilum and retro-hepatic inferior vena cava.

Conditions
-----------------
Surgical Blood Loss

Intervention / Treatment
-----------------
* Procedure: stepwise vascular control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: tumor size is more than 5cm in diameter; these tumor were close to or were compressing main hepatic veins and RIVC directly; Pugh-Child Grade is A or Indocyanine green retention rate at 15min (ICG15%) is less than 10% .

Ages Eligible for Study
-----------------
Minimum Age: 41 Years
Maximum Age: 68 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: stepwise vascular control|Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blood loss during liver resection |  | duration of operation time |
Clinical Evaluation of the GLYDe Dressing for Post-surgical Incision Care

Study Overview
=================
Brief Summary
-----------------
This study will evaluate a new dressing to be used for post-incision care for abdominoplasty patients. The hypothesis is that this dressing will minimize scar formation.

Detailed Description
-----------------
This study will evaluate a new dressing in up to 30 patients who have undergone an abdominoplasty procedure. They will wear the dressing through 8 weeks post surgery and the scar will be evaluated at 3 months post surgery.

Official Title
-----------------
Clinical Evaluation of the GLYDe Dressing for Post-surgical Incision Care

Conditions
-----------------
Post Surgical Incisions From Abdominoplasty Procedures

Intervention / Treatment
-----------------
* Device: GLYDe Dressing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects who have undergone an abdominoplasty 1 week prior to study participation Exclusion Criteria: subjects with a history of collagen vascular disease or scleroderma subjects with known adverse reactions to steri-strips, medical tapes or adhesives

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: GLYDe Dressing<br>Investigational Dressing | Device: GLYDe Dressing<br>* Wound dressing intended to minimize scar formation<br>|
| No Intervention: Standard of Care<br>Standard of care comparator | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scar Evaluation at End of Treatment Period Comparing Treated to Standard of Care (Control) | Professional photographs were taken 12 months postsurgery and evaluated by lay and professional panels. A 100 point Visual Analog Scale (VAS), ranging from a score of 0 for a better outcome to a score of 100 for worse outcome, will be used to assess both the Treated and Control scars at the same timepoint. | through 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
incision, abdominoplasty
Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis

Study Overview
=================
Brief Summary
-----------------
This is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. The objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including dietary supplements, excepting calcium from meals), and to monitor the type, incidence, severity, and relevance of other adverse drug reactions,including urolithiasis.

Official Title
-----------------
EDIROL Drug Intensive Monitoring: Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis

Conditions
-----------------
Postmenopausal Osteoporosis

Intervention / Treatment
-----------------
* Drug: Eldecalcitol soft capsules


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal osteoporosis patients who signed the informed consent form and are expected to receive Edirol during the intensive monitoring period. Patients with postmenopausal osteoporosis Patients who signed the informed consent form Patients who are expected to receive Edirol during planned enrollment period Exclusion Criteria: Exclude if any of the following: Men No osteoporosis Other osteoporosis (not postmenopausal) Started Edirol before ICF signature Did not sign ICF
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Eldecalcitol soft capsules|0.75 μg orally once a day during the intensive monitoring period. (The dose can be appropriately reduced to 0.5 μg according to symptoms, once a day.)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the rates of hypercalcemia and 95% confidence intervals for patients with and without calcium preparation intake |  | one year from Edirol dosing date | 
| the odds ratios of hypercalcemia and 95% confidence intervals for patients with and without calcium preparation intake |  | one year from Edirol dosing date | 
| the proportion of each type of adverse drug reactions (including hypercalcemia, urolithiasis, etc.) |  | through study completion, up to one year | 
| the incidence of adverse drug reactions (including hypercalcemia, urolithiasis, etc.) |  | through study completion, up to one year | 
| the severity of adverse drug reactions (including hypercalcemia, urolithiasis, etc.) |  | through study completion, up to one year |